Evaluating a Severe CSU Case: Angioedema, Emergency Visits, and Uncontrolled Disease

Dr. Chovatiya introduces Case 2: a 52-year-old man with a several-year history of CSU characterized by frequent, widespread wheals and intermittent angioedema affecting the face, lips, and hands, along with occasional throat tightness (but no airway compromise). He has experienced daily symptoms for the past three months, individual wheals resolve within 24 hours without bruising or residual skin changes, and the skin is clear at the time of visit. He has reduced his work travel, stopped going to the gym, and reports significant anxiety about the unpredictable nature of his symptoms—particularly the angioedema episodes. He prefers an oral therapy due to his demanding travel schedule. He has had urgent care and emergency department visits, including a hospitalization in the past year involving progressive throat tightness, hoarseness, and difficulty swallowing, for which he received epinephrine and was discharged with an epinephrine auto-injector and oral corticosteroids. His prior treatment history includes standard-dose and up-dosed second-generation H1 antihistamines, making him formally antihistamine-refractory by guideline criteria.

Dr. Tarbox identifies this immediately as a higher-stakes presentation than Case 1. He is not in the bothersome nuisance category—he is in the safety risk category. She emphasizes the need to evaluate whether his angioedema is occurring in isolation, far removed from urticarial lesions, which would prompt a deeper investigation into bradykinin-mediated causes such as C1 inhibitor deficiency, or rule out ACE inhibitor use. She notes that while severe angioedema in the context of CSU is rare, a small percentage of patients do experience it, and when they do, they tend to have significantly greater overall CSU activity, worse health-related quality of life, higher healthcare utilization, and a longer time to therapeutic response.

She also endorses the decision to discharge him with an epinephrine auto-injector given the circumstances of his hospitalization, while noting she does not routinely prescribe epinephrine to every CSU patient—doing so can cause unnecessary alarm about disease severity. In this case, however, the severity is real and the unpredictability is a genuine source of disability. She emphasizes that this patient needs prompt escalation to an effective therapy to achieve complete disease control.

In the next episode, "Assessing Disease Burden and Transitioning to Advanced Therapy in CSU," the panel explores how to assess the full impact of CSU when the skin looks normal, and how to approach the transition to advanced targeted therapy.